Resitu: minimally invasive surgical technology

News and press releases

Follow Resitu's path towards creating a paradigm shift in the management of breast cancer. Read up on news, press releases and clinical studies.

Sampling in avocado in booth A4 at EBCC

Thanks to everyone who has visited our stand at EBCC. It is soon time to leave Barcelona - but before you do we still have a few avocados left if you have not yet tried the Resitu technology.

At the European Breast Cancer Conference

Discussions in booth A4 at EBCC. Come pay us a visit if you are at the congress.

Resitu Medical at EBCC in Barcelona

Resitu Medical will be in Barcelona at the European Breast Cancer Conference, November 16-18 to present our unique Resitu Technology of minimally invasive lesion removal. If you are in Barcelona, visit us in Booth A4 to learn more!

New seed round

Resitu Medical has closed the second seed round of 1.5 MEUR mainly by existing shareholders. Major shareholders are Novoaim 60%, ALMI Invest 15% and Stockholm Business Angels (STOAF) 15%.

The development of the first instrument is proceeding according to plan. The product design is finalized and is currently being transferred to production. “The funding will be used to verification, validation, clinical studies, and prepare the documentation for CE mark and FDA submission” says CEO Stefan Sowa.

Resitu Medical announces new visual identity and website

Resitu Medical is happy to release our new website, presenting our new visual identity. The new identity illustrates our vision: Beyond Conventional surgery and our Mission: We design for a minimal invasive technology. Our new visual identity harmonizes with the user friendliness and intuitive ease of use of our products in development and that our products are designed with the user in focus. The identity and communication aim to reflect our product message Precision made easy. 

Welcome to look around!

Medlim bootcamp

Resitu Medical has been selected as 1 of 16 companies from 68 applicants for the MedLim Matchmaking & Fast Track Acceleration Program. The program is offered to promising startups that develop breakthrough, innovative MedTech products and services in the Cardiovascular, Neurological, Spine & Medical Surgical domains.

EIT health MedTech Accelerator Bootcamp

Resitu Medical was selected for the EIT Health MedTech Accelerator Bootcamp, a six-week online program for promising start-up companies in the medical technology field arranged by EIT Health in collaboration with UnterNehmerThum, IESE Business school and FAU university. The team completed the training guided by mentors and experts covering many aspects of starting and building a business in this challenging field, including medical device regulations, market access, financing, market and competitor analysis, business case and pitch presentation, and the importance of having the right team.

Resitu Medical wins Healthy Longevity Catalyst Award and receives 50 kUSD

Resitu Medical  is one of 154 winners selected among 1500 applicants from 50 countries to win the Healthy Longevity Catalyst Award from the US National Academy of Medicine,  and receives 50 kUSD. Resitu Medical was selected by EIT Health as 1 of 21 winners  from more than 400 applicants in the European Union.

We would like thank the National Academy of Medicine and EIT Health for selecting Resitu Medical as a winner of the Healthy Longevity Catalyst Award. We aim to contribute to health and longevity by enabling correct and early diagnosis and faster treatment of breast cancer. The true winners will be the women with breast lesions and tumours who will get access to the minimally invasive Resitu technology offering them a fast and safe diagnosis giving better treatment outcomes. Our cost effective technology will also bring substantial health economic gains for the benefit of the society. 

Resitu Medical welcomes Henrik

We are happy to announce that we have recruited Henrik Thunqvist as a new employee. Henrik has collaborated with Resitu Medical when writing his master thesis, to finish his studies of Engineering Physics in Uppsala. 

Almi Invest and STOAF invest in Resitu's new treatment of breast cancer

Almi Invest and STOAF III Scitech invest 2.5 MSEK each in Resitu Medical, for their development of a new instrument for early treatment of breast cancer. Other private investors are also participating in the issue totalling SEK 7.5 million. The money will be used for product development of a version of the instrument ready for CE marking.

€750 000 to EIT Health company Resitu Medical

The medical technology company Resitu Medical AB, working with an innovative solution for tumor biopsies, announced today that Almi Invest, Stockholm Business Angels (STOAF) and private investors have invested €750 000 in the company. The investment will be used to initiate a development project aiming for CE marking in 2023. An additional SEK 20 million will be raised through equity.

Nordic Life Science News

Resitu Medical has received a 50,000 Euro grant from the EIT Health Headstart programme. 

Scandinavian startups receiving in total up to €700,000 in funding

Resitu Medical is one of the Scandinavian startups selected for the 2020 annual EIT Health Headstart programme.

89 startups from across Europe of which 14 are based in Scandinavia are selected for support to accelerate the development of promising health solutions

Resitu

Resitu Medical AB
Rapsgatan 7B
Uppsala, Sweden

info@resitumedical.com

Resitu Medical AB is a Swedish Medical Device company founded in 2019. The company is developing instruments enabling safe removal of intact tissues by a revolutionary technology. The solution has the potential to create a paradigm shift in the management of breast cancer. The portfolio of instruments will speed up the process of cancer management using a minimally invasive approach and facilitating the way radiologists and surgeons work.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.